Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Stay or go?

MicroGeneSys quandary: Stay or go?

WASHINGTON - MicroGeneSys Inc., no longer the exclusive beneficiary of a $20 million appropriation to test its AIDS vaccine and unhappy with the probable conditions of an NIH-run comparison trial of several competing products, now has to decide whether it wants to participate.

The Department of Defense last week finally agreed to transfer the $20 million from the Army, once earmarked for an exclusive trial of MicroGeneSys' gp160 therapeutic vaccine, to the National Institute of Allergy and Infectious Diseases, the NIH organization which conducts AIDS research.

The inter-agency agreement may have resolved a fractious dispute over the funds, which were appropriated by Congress after a high-level lobbying effort

Read the full 1109 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE